Navigation Links
Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
Date:1/12/2009

developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our Annual Report on Form 10-K for the year ended December 31, 2007; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.

Press inquiries: Rochelle Fuhrmann, Senior Director, Investor Relations of Warner Chilcott Limited, +1-973-442-3281, rfuhrmann@wcrx.com or Patty Eisenhaur, Executive Director, Investor Relations of Watson Pharmaceuticals, Inc., 951-493-5611, patty.eisenhaur@watson.com

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press release
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.; Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
2. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
3. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
4. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
5. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference
6. Warner Chilcott Announces 2008 Financial Guidance
7. Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director
8. Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
9. CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN
10. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
11. Warner Chilcott Announces Settlement of Securities Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... French . By ... including brain structure and function, personality, life experiences and genetics, ... to develop binge drinking within the next two years. Impulsivity, ... as life events and a family history of drug use ... not the child had had a single drink at age ...
(Date:7/9/2014)... highlights, Brian Williams refreshing old school rap classics, and ... A University of Colorado Cancer Center study published in ... also allows researchers, journals, and health advocates to connect ... and prevention. , "No matter what field you,re in, ... around the world," says Chante Karimkhani, MD candidate in ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... study published in the scientific journal Nature Neuroscience ... researchers at Universit Laval, reveals that it is possible ... involves rekindling pain so that it can subsequently be ... alleviate chronic pain. , The researchers from the Faculty ... sant mentale de Qubec (IUSMQ) were inspired by previous ...
(Date:7/8/2014)... in Memory Restoration has been awarded up to $15 ... for a four -year project aiming to help brain-injured ... experts in neurosurgery, engineering, neurobiology, psychology and physics will ... prosthesis in the brain. , Memory is the process ... encode information, store it and retrieve it. Certain types ...
Breaking Medicine News(10 mins):Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3
... Will Set Key Industry Records, CARROLLTON, Texas, Sept. ... of medical imaging facilities, has,announced it has begun construction ... project, in Sherman, Texas, represents several,firsts of its kind. ... Texas, it is the first,joint venture between multiple hospitals ...
... and Wolf Haldenstein Obtain Third-Largest Settlement,in Securities Fraud ... PHILADELPHIA, Sept. 10 Judge Morris E.,Lasker of ... Massachusetts has,granted final approval of a $52.5 million ... against Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: ...
... provides evidence that noncoding RNAs and interactions between noncoding ... than was previously understood. The research, published by Cell ... Cell, may be useful for identifying tumor-specific signatures associated ... cells exhibit genetic alterations in oncogenes or tumor suppressor ...
... has been made by McMaster researchers about Fragile X ... one in 4,000 males and one in 6,000 females. ... associated with mental impairment. The affected gene (FMR1) leads ... the fragile X mental retardation protein (FMRP). , ...
... ... Conference, Majority of Students Polled Think Health Centers Need to Improve their ... ... 2007 Sexual Health Report Card, the second,annual ranking of sexual health resources at American colleges ...
... CITY, Calif., Sept. 10 Genomic,Health, Inc. (Nasdaq: ... studies that,support the use of quantitative real-time polymerase ... assay, for measuring the hormone,receptors, estrogen receptor (ER) ... A separate study identified multiple genes,including the 21 ...
Cached Medicine News:Health News:Fry Construction Selected for High-Profile Medical Imaging Project 2Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas 2Health News:Stem cell research produces a key discovery for Fragile X Syndrome 2Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 2Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 3Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 4Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 5Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 6Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 7Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 8Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 9Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 10Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 11Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 2Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 3Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 4
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... March 20 Valor Medical, an emerging medical,device company ... human,implant of Neucrylate AN for treatment of cerebral aneurysms ... Tehran. The treatment was under the,guidance of a clinical ... Committee., Dr. Pakbaz stated that the patient,s aneurysm ...
... for more ... anticoagulation patients, INDIANAPOLIS, March ... meter training, equipment and supplies for all long-term,warfarin users who ... The change opens the door to greater convenience and,potentially fewer ...
Cached Medicine Technology:Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 2Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 3Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 4
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... PVC. 2 eyes, oral. Marked with ... X-ray opaque line. Graduated. Single use. ... reduce kinking of the tube by ... adapts to the anatomical situation at ...
... Ruschelit® PVC. Murphy eye-oral. High volume/low ... Oral Cuffed Single use. For improved ... of the tube by incorporating a ... cuff. Thermosensitive Ruschelit® PVC adapts to ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Medicine Products: